Urinary Bladder Neoplasms × Head & Neck × Clear all
NCT06910657 2026-03-02

IDOV-Immune for Advanced Solid Tumors

ViroMissile, Inc.

Phase 1 Recruiting
78 enrolled
NCT07124000 2026-02-24

DP-04

AstraZeneca

Recruiting
100 enrolled
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
NCT05267626 2026-02-18

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Aulos Bioscience, Inc.

Phase 1/2 Recruiting
159 enrolled
NCT04459273 2026-02-05

FAPI PET RDRC

Jonsson Comprehensive Cancer Center

Phase 1 Active not recruiting
26 enrolled
NCT06242470 2026-02-05

A Study of MGC026 in Participants With Advanced Solid Tumors

MacroGenics

Phase 1 Recruiting
250 enrolled
NCT05334069 2026-02-04

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Alliance for Clinical Trials in Oncology

Recruiting
2,000 enrolled
NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

City of Hope Medical Center

Phase 1 Active not recruiting
11 enrolled
NCT06172478 2026-01-28

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Daiichi Sankyo

Phase 2 Recruiting
740 enrolled
NCT02012699 2026-01-22

iCaRe2

University of Nebraska

Recruiting
999,999 enrolled
NCT05366881 2026-01-20

CAMPERR

Adela, Inc

Recruiting
7,000 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT06022029 2025-12-24

ON-5001

OncoNano Medicine, Inc.

Phase 1 Recruiting
168 enrolled
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
NCT03452774 2025-10-28

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc.

Recruiting
50,000 enrolled
NCT06171945 2025-10-27

AYAConnect

UNC Lineberger Comprehensive Cancer Center

Phase NA Completed
63 enrolled
NCT06336148 2025-10-15

A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors

Actym Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
NCT05461430 2025-09-15

TraveraRTGx

Travera Inc

Recruiting
200 enrolled
NCT06582849 2025-08-26

EARN

Washington University School of Medicine

Phase NA Completed
33 enrolled
NCT07118176 2025-08-12

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Jonsson Comprehensive Cancer Center

Phase 1 Recruiting
30 enrolled
NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Incyte Corporation

Phase 1 Completed
260 enrolled 52 charts
NCT05563272 2025-07-10

STARBURST

Telix Pharmaceuticals (Innovations) Pty Limited

Phase 2 Terminated
11 enrolled
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled